Last updated: March 19, 2024
Sponsor: Vanda Pharmaceuticals
Overall Status: Active - Recruiting
Phase
3
Condition
Sleep Disorders
Autism
Asperger's Disorder
Treatment
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Clinical Study ID
NCT05361707
VP-VEC-162-3601
Ages 2-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Ability and acceptance to provide written informed consent of the participant or legalguardian (and assent as required).
- A confirmed clinical diagnosis of Autism Spectrum Disorder (ASD) and a recent historyof sleep disturbances.
- The sleep disturbance must not be a result of another diagnosable disorder ormedication.
- Male or female between 2 and 65 years of age, inclusive.
- Willing and able to comply with study requirements and restrictions.
Exclusion
Exclusion Criteria:
- Inability to dose daily with tasimelteon or previous intolerance to tasimelteon.
- Indication of impaired liver function.
- Evidence of increased risk of self-harm.
- Pregnant or lactating females.
- A positive test for drugs of abuse.
- Other diagnosable causes of sleep disorders or use of medications that may causesedation or stimulation.
Study Design
Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Phase: 3
Study Start date:
July 28, 2021
Estimated Completion Date:
July 31, 2025
Connect with a study center
Vanda Investigational Site
San Jose, California 95124
United StatesActive - Recruiting
Vanda Investigational Site
San Leandro, California 94578
United StatesActive - Recruiting
Vanda Investigational Site
Santa Monica, California 90404
United StatesActive - Recruiting
Vanda Investigational Site
Boulder, Colorado 80301
United StatesActive - Recruiting
Vanda Investigational Site
Staten Island, New York 10312
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.